Skip to Content

LogicBio Therapeutics, Inc.

Merger

  • Date:
  • 10/3/2022
  • Company Name:
  • LogicBio Therapeutics, Inc.
  • Stock Symbol:
  • LOGC
  • Company Name - Buyer:
  • AstraZeneca Rare Disease
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 10/3/2022

Case Finder

Locate any case using the tools below.

NEW YORK, October 3, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) (“LogicBio”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by AstraZeneca Rare Disease.

On October 3, 2022, LogicBio announced that it had entered into an agreement to be acquired by AstraZeneca Rare Disease in an all-cash deal. Pursuant to the merger agreement, AstraZeneca Rare Disease will initiate a cash tender offer to acquire all outstanding shares of LogicBio for $2.07 per share. The deal is expected to close in the next four to six weeks.

Bragar Eagel & Squire is concerned that LogicBio’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for LogicBio’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in LogicBio Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: